Sign in to view content

Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

Carl D. Regillo, MD

Video
Published 2019

Carl D. Regillo, MD, FACS

AMD Neovascular Part I

Related

Episode 32 - Change in Management after Vitreous Culture in Endophthalmitis after Intravitreal Injections-Dr. James Vander
Keyvan Koushan, MD, FRCSC
Member Podcasts
2020
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018
Subfoveal Choroidal Thickness as a Prognostic Factor in Exudative Age related Macular Degeneration.
Jaya B. Kumar, MD, FASRS
On Demand Cases, Courses, and Papers
2017

Category: AMD-Neovascular

See more